Микардис в ежедневной клинической практике: больше, чем просто снижение артериального давления

блокада ренин-ангиотензиновой системы, прогноз, органопротекция, телмисартан

1. Tigerstedt R., Bergman P.G. Nierre und Kreislauf // Skand. Arch. Physiol. - 1898. - Vol. 8. - P. 223-271.

2.

3. Kurtz T.W., Klein U. Next generation multifunctional angiotensin receptor blockers // Hypertens. Res. - 2009. - Vol. 32, № 10. - P. 826-834. 3.

4.

5. Galzerano D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Galzerano%20D%22%5BAuthor%5D>., Capogrosso C <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Capogrosso%20C%22%5BAuthor%5D>., Di Michele S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Di%20Michele%20S%22%5BAuthor%5D>. et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan // Vasc. Health Risk Manag. <javascript:AL_get(this,%20'jour',%20'Vasc%20Health%20Risk%20Manag.');> - 2010. -Vol. 6. - P. 113-33.

6.

7. Nesbitt S.D., Julius S., Leonard D., Egan B.M., Grozinski M., TROPHY study investigators. Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY study <http://www.ncbi.nlm.nih.gov/pubmed/16053996> // Am. J. Hypertens. - 2005. - Vol. 18, № 7. - P. 980-985.

8.

9. Derosa G., Ragonesi P., Mugellini A., Ciccarelli L., Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glukose metabolism and lipid profile in hypertensive, type II diabetic patients: a randomized, double-blind, placebo-controlled 12-month study // Hypertens. Res. - 2004. - Vol. 27, № 7. - P. 457-464.

10.

11. Mallion J.M., Siché J.P., Lacourcière Y., the telmisartan blood pressure monitoring group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension // J. Hum. Hypertens. - 1999. - Vol. 13, № 10. - P. 657-664.

12.

13. Smith D.H., Cramer M.J., Neutel J.M., Hettiarachchi R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hettiarachchi%20R%22%5BAuthor%5D>., Koval S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Koval%20S%22%5BAuthor%5D>. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies // Blood Press. Monit. - 2003. - Vol. 8, № 3. - P. 111-117.

14.

15. Sasaki T., Noda Y <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Noda%20Y%22%5BAuthor%5D>., Yasuoka Y <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yasuoka%20Y%22%5BAuthor%5D>., et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome // Hypertens. Res. - 2008. - Vol. 31, № 5. - P. 921-929. 9.

16.

17. Lacourcière Y., Neutel J.M., Davidai G. , Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring // Am. J. Hypertens. - 2006. - Vol. 19. - P. 104-112.

18.

19. Nalbantgil I., Nalbantgil S., Özerkan F. et al. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension // Int. J. Clin. Pract. - 2004. -Vol. 58, № 145. - P. 50-54.

20.

21. Neutel J.M., Frishman W.H., Oparil S., Papademitriou V <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Papademitriou%20V%22%5BAuthor%5D>., Guthrie G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Guthrie%20G%22%5BAuthor%5D>. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension // Am. J. Ther. - 1999. - Vol. 6, № 3. - P. 161-166.

22.

23. Galzerano D., Tammaro P., del Viscovo L. et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study // Am. J. Hypertens. - 2005. - Vol. 18, № 12, Pt. 1. - P. 1563-1569. 13.

24.

25. Lacourcière Y., Lenis J., Orchard R. et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine // Blood Press. Monit. - 1998. - Vol. 3, № 5. - P. 295-302.

26.

27. Derosa G., Cicero A.F.G., Bertone G. et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study // Clin. Ther. - 2004. - Vol. 26, № 8. - P. 1228-1236.

28.

29. Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients - a metaanalysis of 109 treatment studies // Am. J. Hypertens. - 1992. -Vol. 5, № 2. -P. 95-110.

30.

31. Dahlof B., Zanchetti A., Diez J. et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy // J. Hypertens. - 2002. - Vol. 20, № 9. - P. 1855-1864. 17.

32.

33. Wachtell K <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wachtell%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>., Okin P.M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Okin%20PM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>., Olsen M.H <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Olsen%20MH%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>. et al.Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study // Circulation. <javascript:AL_get(this,%20'jour',%20'Circulation.');> - 2007. -Vol. 116, № 7. - P. 700-705.

34.

35. Klingbeil A.U., Schneider M., Martus P., Messerli F.H., Schmieder R.E. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension // Am. J. Med. - 2003. - Vol. 115, № 1. - P. 41-46. 19.

36.

37. Mansia G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mansia%20G%22%5BAuthor%5D>., De Backer G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22De%20Backer%20G%22%5BAuthor%5D>., Dominiczak A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dominiczak%20A%22%5BAuthor%5D>. et al. European Society of Hypertension <http://www.ncbi.nlm.nih.gov/pubmed?term=%22European%20Society%20of%20Hypertension%22%5BCorporate%20Author%5D>; European Society of Cardiology <http://www.ncbi.nlm.nih.gov/pubmed?term=%22European%20Society%20of%20Cardiology%22%5BCorporate%20Author%5D>. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Blood Press. <javascript:AL_get(this,%20'jour',%20'Blood%20Press.');> - 2007. - Vol. 16, № 3. - P. 135-232.

38.

39. Galzerano D., Tammaro P., Cerciello A. et al. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study // J. Hum. Hypertens. - 2004. - Vol. 18, № 1. - P. 53-59.

40.

41. Weber K.T., Sun G., Campbell S.E. Structural remodelling of the heart by fibrosis tissue: role of circulating hormones and locally produced peptides // Eur. Heart J. - 1995. - Vol. 16, Supp. l. - P. 80-85.

42.

43. Rosendorff C. Vascular hypertrophy in hypertension: role of the renin-angiotensin system // Mt. Sinai. J. Med. - 1998. - Vol. 65, № 2. - P. 108-117.

44.

45. Chrysant S.G. Vascular remodeling: the role of angiotensin-converting enzyme inhibitors // <http://www.ncbi.nlm.nih.gov/pubmed/9488609?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum> Am. Heart. J. - 1998. - Vol. 135, № 2, Pt. 2. - P. S21-S30.

46.

47. Asmar R., Gosse P., Topouchian J., N'tela G., Dudley A., Shepherd G.L. Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension // J. Renin Angiotensin Aldosterone Syst. - 2002. - Vol. 3, № 3. - P. 176-180.

48.

49. Uchida H., Nakamura Y., Kaihara M. et al. Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension // Hypertens. Res. - 2004. - Vol. 27, № 8. - P. 545-550.

50.

51. Schmieder R.E., Delles C., Mimran A., Fauvel J.P., Ruilope L.M. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes // Diabetes Care. - 2007. - Vol. 30, № 6. - P. 1351-1356.

52.

53. Zankl A.R., Ivandic B <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ivandic%20B%22%5BAuthor%5D>., Andrassy M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Andrassy%20M%22%5BAuthor%5D>. et al. Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease // Clin. Res. Cardiol. <javascript:AL_get(this,%20'jour',%20'Clin%20Res%20Cardiol.');> - 2010. - Vol. 99, № 12. - P. 787-794. 28.

54.

55. Wago T <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wago%20T%22%5BAuthor%5D>., Yoshimoto T <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yoshimoto%20T%22%5BAuthor%5D>., Akaza I <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Akaza%20I%22%5BAuthor%5D>. et al. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan // Hypertens. Res. <javascript:AL_get(this,%20'jour',%20'Hypertens%20Res.');> - 2010. - Vol. 33, № 8. - P. 796-801.

56.

57. Bakris G., Burgess E., Weir M., Davidai G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Davidai%20G%22%5BAuthor%5D>., Koval S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Koval%20S%22%5BAuthor%5D>., AMADEO Study Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22AMADEO%20Study%20Investigators%22%5BCorporate%20Author%5D>. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy // Kidney Int. - 2008. - Vol. 74, № 3. - P. 364-369.

58.

59. Symeonides P., Koulouris S., Triantafyllou K. et al. Favourable pleiotropic effects of ramipril and telmisartan on vascular endothelium of diabetics // J. Am. Coll. Cardiol. - 2005. - Vol. 45, Suppl. A. - P. 428A109.

60.

61. Galle J., Schwedhelm E., Pinnetti S., Böger R.H., Wanner C. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy // Nephrol. Dial. Transplant. - 2008. - Vol. 23, № 10. - P. 3174-3183.

62.

63. Yusuf S., Teo K.K., Pogue J. et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. - 2008. - Vol. 358, № 15. - P. 1547-1559.

64.

65. Yusuf S., Teo K., Anderson C. et al., TRANSCEND Investigators, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // Lancet. - 2008. - Vol. 372, № 9644. - Р. 1174-1183. 34.

66.

67. Galzerano D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Galzerano%20D%22%5BAuthor%5D>., Capogrosso C <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Capogrosso%20C%22%5BAuthor%5D>., Di Michele S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Di%20Michele%20S%22%5BAuthor%5D>. et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan // Vasc. Health Risk Manag. <javascript:AL_get(this,%20'jour',%20'Vasc%20Health%20Risk%20Manag.');> - 2010. - Vol. 6. - P. 113-133.